Search Results

Your search for Julie M. Vose, MD, MBA matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / Pan Pacific Lymphoma Conference 2018

Julie M. Vose, MD, MBA, and David G. Maloney, MD, PhD, on NHL: Update on CAR T-Cell Therapies

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center and winner of this year’s Oliver Press Memorial Award, discuss three CAR T-cell products for lymphoma treatment, comparing their efficacy, toxicity, ease of ...

lymphoma

immunotherapy

By The ASCO Post Staff / 2018 ASCO Annual Meeting

Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on lenalidomide plus rituximab vs chemotherapy plus rituximab, followed by rituximab maintenance, in patients with ...

Apr

Today In Oncology

Search Results

Your search for Julie M. Vose, MD, MBA matches 2 pages

Julie M. Vose, MD, MBA, and David G. Maloney, MD, PhD, on NHL: Update on CAR T-Cell Therapies

Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial

Insights From the 2023 International Society of Geriatric Oncology Conference

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Oxaliplatin-Based Adjuvant Therapy in Older Patients with Stage III Colon Cancer

Newly Diagnosed Locally Advanced HNSCC Adding Pembrolizumab to Concurrent Chemoradiotherapy

Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone